SCHEMBL19492615

SCHEMBL19492615

Cc1nn2c(C(C)C)c(C(=O)O)cnc2c1Br

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ POLB P06746 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ MAPT P10636 5/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ NR3C1 P04150 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19492644 0.89 ALDH1A1 (0.40) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL19463663 0.83 KDM4E (0.50) KDM4EALDH1A1POLBLMNAHTT
SCHEMBL20768126 0.83 ALDH1A1 (0.35) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL28630088 0.81 KDM4E (0.43) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL19464016 0.81 PPARA (0.37) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL28619853 0.80 KDM4E (0.42) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL28634209 0.78 HPGD (0.43) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL19464294 0.78 KDM4E (0.40) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL19492870 0.78 TDP1 (0.41) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL19464269 0.77 ALDH1A1 (0.40) KDM4EALDH1A1TDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024213752-A1 LONG-TERM PREVENTION AND/OR TREATMENT OF A DISEASE BY SLO-1 INHIBITORS ELANCO ANIMAL HEALTH GMBH (DE) 2024-10-17 — — WO disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
CN-109071545-B Novel pyrazolopyrimidine derivatives 拜耳动物保健有限责任公司 2021-08-03 — — CN disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-10604525-B2 Pyrazolopyrimidine derivatives BAYAL ANIMAL HEALTH GMBH (DE) 2020-03-31 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
WO-2017178416-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604525-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1438/4885ALDH1A1 1297/4885TDP1 1732/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1445/4885ALDH1A1 1228/4885TDP1 1742/4885
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1438/4885ALDH1A1 1297/4885TDP1 1732/4885
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1445/4885ALDH1A1 1228/4885TDP1 1742/4885
US-10934301-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1445/4885ALDH1A1 1228/4885TDP1 1742/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1658/4885ALDH1A1 1241/4885TDP1 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback